Gathers health information from younger patients with cancer over time
Collects health information from children and young people with several cancers.
Plain-language title generated from the registry record
Registry title: Project: Every Child for Younger Patients With Cancer
Key facts
- Where
- Calgary, Edmonton, Halifax, Hamilton, Kingston, London, Montreal, Ottawa, Québec, Saskatoon, Sherbrooke, St. John's, Toronto, Vancouver, and Winnipeg, CanadaSee the 17 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children, teens and young adults with a known or suspected cancer or related tumor. It collects health information over time.
- Age
- 25 years or younger at the time of the original diagnosis. A higher age limit applies to people screened for some treatment studies.
- Sex
- All sexes can join.
- Disease stage
- Known or suspected tumor that occurs in children, teens or young adults. This includes all cancers, all tumors of the brain and nervous system, and all tumors of the kidney. Some benign or borderline conditions are also included. Joining must happen within 6 months of first diagnosis, or within 6 months of the disease not responding, getting worse, coming back, or a second cancer.
Main reasons for not taking part
- Over 25 years old at original diagnosis (except for some treatment study screening)
- No signed informed consent from the patient, parent or legal representative
- Clearly benign nevi (moles)
Read by machine on 12 November 2026.
Where in Canada
- Alberta Children's HospitalCalgary, CanadaContact: Victor A. Lewis (principal investigator)Taking people
- University of Alberta HospitalEdmonton, CanadaContact: Sarah J. McKillop (principal investigator)Taking people
- IWK Health CentreHalifax, CanadaContact: Chelsea Ash (principal investigator)Taking people
- McMaster Children's Hospital at Hamilton Health SciencesHamilton, CanadaContact: Uma H. Athale (principal investigator)Taking people
- Kingston Health Sciences CentreKingston, CanadaContact: Laura Wheaton (principal investigator)Taking people
- Children's HospitalLondon, CanadaContact: Shayna M. Zelcer (principal investigator)Taking people
- Centre Hospitalier Universitaire Sainte-JustineMontreal, CanadaContact: Monia Marzouki (principal investigator)Taking people
- The Montreal Children's Hospital of the MUHCMontreal, CanadaContact: Stephanie Mourad (principal investigator)Taking people
- Children'S Hospital Of Eastern OntarioOttawa, CanadaContact: Donna L. Johnston (principal investigator)Taking people
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)Québec, CanadaContact: Bruno Michon (principal investigator)Taking people
- Jim Pattison Children's HospitalSaskatoon, CanadaContact: Kathleen Felton (principal investigator)Taking people
- Saskatoon Cancer CentreSaskatoon, CanadaNo longer taking part
- Centre Hospitalier Universitaire de Sherbrooke-FleurimontSherbrooke, CanadaContact: Josee Brossard (principal investigator)Taking people
- Janeway Child Health CentreSt. John's, CanadaContact: Lisa A. Goodyear (principal investigator)Taking people
- Hospital for Sick ChildrenToronto, CanadaNo longer taking part
- British Columbia Children's HospitalVancouver, CanadaContact: Rebecca J. Deyell (principal investigator)Taking people
- CancerCare ManitobaWinnipeg, CanadaContact: Stephanie M. Villeneuve (principal investigator)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Children's Oncology Group
- Trial code
- NCT02402244
- Record updated
- 25 August 2026
- Original description
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.Read full original descriptionShow less
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Inclusion: Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem; Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority; Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:; All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one "1" (borderline), two "2" (carcinoma in situ) or three "3" (malignant); All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant; All neoplastic lesions of the kidney regardless of behavior, i.e., benign, borderline or malignant; The following other benign/borderline conditions:; Mesoblastic nephroma; Teratomas (mature and immature types); Myeloproliferative diseases including transient myeloproliferative disease; Langerhans cell histiocytosis; Lymphoproliferative diseases; Desmoid tumors; Gonadal stromal cell tumors; Neuroendocrine tumors including pheochromocytoma; Melanocytic tumors, except clearly benign nevi; Ganglioneuromas; Subjects must be =< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network [NCTN]) therapeutic study, for which there is a higher upper age limit; All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission; If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1.